HOME >> BIOLOGY >> NEWS
Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack

San Diego, CA, September 27, 2004 - MacroPore Biosurgery, Inc. (Frankfurt: XMP) today announced that adipose tissue-derived regenerative cells improved heart function following myocardial infarction in a large-animal preclinical safety study. This study, performed in swine, confirms previous preclinical work by MacroPore Biosurgery and others suggesting that the Company's proprietary, patented technology is safe and may be clinically useful in treating heart disease. The goal of the study was to determine the safety of adipose tissue-derived regenerative cells delivered into coronary circulation without cell culture. The results were presented in a poster presentation at the Transcatheter Cardiovascular Therapeutics 2004 meeting in Washington D.C. (Abstract # 550778).

Intracoronary infusion of adipose tissue-derived regenerative cells 48 hours after infarction was found to be safe, with all 13 swine surviving to the 6-month follow-up period. Additionally, the study demonstrated a statistically significant improvement in left ventricular ejection fraction (LVEF) at six-months post-infarction in the treated group over the control group, as measured by 2D echocardiography. Similar trends were observed by measuring LVEF via cineangiography, as provided in the data table below. LVEF is a measure of the heart's ability to pump oxygenated blood throughout the body. It specifically determines the fraction of blood that is ejected out of the left ventricle with each contraction.

"We are encouraged by the findings from this preclinical study, which suggest that delivery of autologous, adipose tissue-derived, regenerative cells is safe and effective in preserving left ventricular systolic function," said John K. Fraser, Vice President, Research and Technology, of MacroPore Biosurgery. "Despite the fact that this study was designed primarily to evaluate the safety of dose escalation in limited infarcts, we observed statistically significant improvements in h
'"/>

Contact: Tom Baker
tbaker@macropore.com
858-232-7234
Cytori Therapeutics
27-Sep-2004


Page: 1 2 3

Related biology news :

1. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
2. Encouraging Results In Preclinical Studies Of Parkinsons Disease Gene Therapy
3. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
4. Plant pathologists meeting in Anaheim, CA to discuss agricultural security, food safety, and more
5. Plant pathologists to meet in Anaheim, CA to discuss agricultural security, food safety, and more
6. Invention could improve PVC safety and strengthen $1.8-billion industry worldwide
7. Educational program increases some safety behaviors for older drivers
8. UNC study may improve gene therapy safety
9. Risk and food are on the same plate: World food safety experts offer new methods to assess risk
10. Study explores safety of low-dose radiation
11. Americans knowledge of genetically modified foods remains low and opinions on safety still split

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/14/2019)... ... January 14, 2019 , ... CellMax ... cancer cells in blood, will present new findings at the ASCO Gastrointestinal Cancer ... colorectal cancer. The results from this study show CellMax Life’s blood test, based ...
(Date:1/10/2019)... (PRWEB) , ... January 09, 2019 , ... Dr. Beanlands ... Heart Institute in Ottawa, Ontario, Canada. He is also Director of its National ... of Medicine, in the Department of Radiology, and in the Department of Cellular and ...
(Date:1/10/2019)... ... 2019 , ... A major goal for pharmaceutical companies has ... significantly more expensive in vivo studies in order to reduce costs and improve ... researchers have begun to adopt 3D cell culture models which have been shown ...
Breaking Biology News(10 mins):
(Date:12/20/2018)... ... December 20, 2018 , ... New Year’s brings reflection ... changes in regulations in the European Union (EU) on the horizon, Jim Kasic, president ... , “The transition to the EU Medical Device Regulation (MDR), digital health, and big ...
(Date:12/18/2018)... ... December 18, 2018 , ... Patients with early stages of breast cancer who ... post-treatment versus whole breast irradiation, a new study suggests. , Patients with early stage ... irradiation after removal of the cancerous tumor because there is a 30 to 40 ...
(Date:12/13/2018)... ... December 13, 2018 , ... Microbial Discovery Group LLC (MDG) ... been part of their strategic plan and an important milestone in increasing their ... opportunities for MDG within the $44 Billion human probiotic market. This plan is ...
(Date:12/5/2018)... (PRWEB) , ... December 04, ... ... an established North American full-service contract research organization (CRO), announced the acquisition ... transaction significantly strengthens ARG’s reach and experience in the management of clinical ...
Breaking Biology Technology:
Cached News: